4 completed, 4 terminated, 1 unknown. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 2, Unknown 1 |
| Phase 2 | 5 | Terminated 4, Unknown 1 |
Follow Proacta, Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors PR610 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | Proacta, Incorporated | 33 | 2012-08-01 | 2014-06-16 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PR104 - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Proacta, Incorporated | 50 | 2010-01-01 | 2012-08-31 |
| Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) PR104, docetaxel, Granulocyte colony-stimulating factor - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Proacta, Incorporated | 42 | 2009-03-01 | 2013-01-10 |
| Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | Proacta, Incorporated | 14 | 2009-03-01 | 2013-08-23 |
| PR104 and G-CSF in Treating Patients With Solid Tumors filgrastim, PR104, F-18-fluoromisonidazole - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 5 | 2008-02-01 | 2011-06-01 |
| PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer PR104, F-18-fluoromisonidazole - Lung Cancer | Phase 2 | Terminated | Proacta, Incorporated | 5 | 2007-08-01 | 2012-12-10 |
| PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors PR-104, docetaxel, gemcitabine hydrochloride - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 42 | 2007-02-01 | 2011-03-02 |
| A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors PR104 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 26 | 2006-12-01 | 2011-05-24 |
| PR-104 in Treating Patients With Advanced Solid Tumors PR-104, laboratory biomarker analysis, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 27 | 2005-12-01 | 2012-11-30 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Carcinoma, Hepatocellular (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Small Cell Lung Carcinoma (1)
PR-104 (5) · Docetaxel (2) · Granulocyte Colony-Stimulating Factor (2) · fluoromisonidazole (2) · Filgrastim (1) · Gemcitabine (1) · Sorafenib (1)
United States (8) · New Zealand (5) · Canada (1) · Hong Kong (1) · Singapore (1) · Taiwan (1)
Mark D. Pegram, MD (1) · Mark McKeage, PhD, FRACP (1) · Terri J. Melink, NP, MSN, ANP (1)
PMID 20012293, PMID 23098625, PMID 25682597
P30CA016042 (1)